Position in EXEL
as of Mar 31, 2026
· filed Apr 14, 2026
Position Value
$600
-$13 QoQ
Shares Held
14
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026USA FINANCIAL FORMULAS holds $1,729,226 across 7 Biotechnology names. EXEL ranks #7 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,457 | $1,125,736 | |
| 2 | INCY |
Incyte Corp
|
5,204 | $489,800 | |
| 3 | KRYS |
Krystal Biotech, Inc.
|
171 | $44,172 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
216 | $43,124 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
132 | $24,954 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
13 | $840 | |
| 7 | EXEL |
Exelixis, Inc.
This page
|
14 | $600 |
All Filings in EXEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $600 | 14 | Shares | Sole | 2026-04-14 | |
| 2025-12-31 | $613 | 14 | Shares | Sole | 2026-01-14 | |
| 2025-06-30 | $298,553 | 6,773 | Shares | Sole | 2025-07-18 | |
| 2025-03-31 | $366,615 | 9,930 | Shares | Sole | 2025-04-15 | |
| 2024-12-31 | $32,234 | 968 | Shares | Sole | 2025-01-14 | |
| 2023-12-31 | $49,419 | 2,060 | Shares | Sole | 2024-02-07 | |
| 2023-09-30 | $2,731 | 125 | Shares | Sole | 2023-11-27 | |
| No filing history on record for this holder in this stock. | ||||||